Table 1:
Checkpoint Inhibitors in HNSCC
| Immunotherapeutic | Target | Select Ongoing Trials |
|---|---|---|
| Pembrolizumab (Pembro) | PD-1 |
NCT03546582 (KEYSTROKE) – SBRT +/− Pembro
in recurrent or secondary primary HNSCC NCT02641093 – Pembro + adjuvant RT or CRT (cisplatin) after surgery in HNSCC NCT02296684 – Neoadjuvant Pembro + SOC (surgery or RT) in high risk HNSCC NCT03765918 – Pembro before surgery and Pembro +/− Cisplatin and RT post-operatively in Stage III-IV LA HNSCC |
| Nivolumab (Nivo) | PD-1 |
NCT03521570 – IMRT + Nivo for recurrent or second
primary HNSCC after prior RT (resectable or eligible for curative
re-irradiation) NCT03576417 – SOC (C/RT) +/− Nivo in HNSCC NCT03247712 – Nivo + RT prior to surgical resection of HNSCC |
| Atezolizumab | PD-L1 |
NCT03452137 - Atezolizumab or placebo as adjuvant
therapy after definitive local therapy in high-risk LA
HNSCC NCT03708224 – Effect of neoadjuvant Atezolizumab prior to surgical resection in HNSCC NCT03818061 - Atezolizumab + Bevacizumab in recurrent/metastatic previously treated HNSCC |
| Durvalumab | PD-L1 |
NCT03212469 – Durvalumab + RT or Durvalumab +
Tremelimumab and SBRT in metastatic HNSCC (also includes lung and
esophageal tumors) NCT02997332 (MEDINDUCTION) - Durvalumab + Docetaxel, Cisplatin and 5-FU for LA HNSCC NCT03635164 - Radiotherapy + Durvalumab before surgical resection for HPV Negative HNSCC |
| Avelumab | PD-L1 |
NCT03498378 - Avelumab, Cetuximab, and Palbociclib in
recurrent/metastatic HNSCC NCT02999087 - Avelumab-cetuximab-radiotherapy vs SOCs in LA HNSCC NCT03260023 - TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies (including OPSCC) |
| Ipilimumab | CTLA-4 |
NCT02812524 - Intratumoral injections of ipilimumab
prior to surgical resection in HNSCC NCT03799445 - Ipilimumab, Nivolumab, and RT for HPV positive OPSCC |
| Tremelimumab | CTLA-4 |
NCT03522584 – Tremelimumab + Durvalumab +
hypofractionated RT in recurrent/metastatic
HNSCC NCT03212469 – Durvalumab + RT or Durvalumab + Tremelimumab and SBRT in metastatic HNSCC (also includes lung and esophageal tumors) NCT02551159 (KESTREL) – MEDI 4736 +/− Tremelimumab vs. SOC in recurrent/metastatic HNSCC (Active, not recruiting) |
| Relatlimab | Lag-3 | NCT04080804 - Nivolumab +/− Relatlimab or Ipilimumab in Head and Neck Cancer |
HNSCC – Head and Neck Squamous Cell Carcinoma, OPSCC – Oropharynx Squamous Cell Carcinoma, RT – Radiation Therapy, CRT – Chemoradiation Therapy, LA – locally Advanced, SBRT - Stereotactic Body Radiation Therapy, SOC – Standard of Care